Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SLC6A2 | P23975 | 6/20 | 0.57 |
| ▸ | SLC6A4 | P31645 | 6/20 | 0.57 |
| ▸ | SLC6A3 | Q01959 | 6/20 | 0.57 |
| ▸ | KCNH2 | Q12809 | 5/20 | 0.57 |
| ▸ | DRD2 | P14416 | 3/20 | 0.47 |
| ▸ | CYP2D6 | P10635 | 4/20 | 0.47 |
| ▸ | SIGMAR1 | Q99720 | 1/20 | 0.45 |
| ▸ | DRD3 | P35462 | 2/20 | 0.45 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL27015512 | 0.92 | DRD2 (0.53) | SLC6A2SLC6A4SLC6A3KCNH2DRD2 | |
| SCHEMBL13698247 | 0.88 | DRD2 (0.60) | SLC6A2SLC6A4SLC6A3KCNH2DRD2 | |
| SCHEMBL13698237 | 0.86 | DRD2 (0.48) | SLC6A2SLC6A4SLC6A3KCNH2DRD2 | |
| SCHEMBL13698261 | 0.85 | DRD3 (0.61) | SLC6A2SLC6A4SLC6A3KCNH2DRD2 | |
| SCHEMBL10163596 | 0.84 | MAPT (0.49) | SLC6A2SLC6A4SLC6A3KCNH2DRD2 | |
| SCHEMBL24685377 | 0.84 | DRD3 (0.62) | SLC6A2SLC6A4SLC6A3KCNH2DRD2 | |
| SCHEMBL10162752 | 0.84 | SLC6A2 (0.48) | SLC6A2SLC6A4SLC6A3KCNH2DRD2 | |
| SCHEMBL13698262 | 0.83 | SLC6A2 (0.57) | SLC6A2SLC6A4SLC6A3KCNH2DRD2 | |
| SCHEMBL10162866 | 0.81 | SMN1; SMN2 (0.47) | SLC6A2SLC6A4SLC6A3KCNH2DRD2 | |
| SCHEMBL1824340 | 0.80 | SLC6A2 (0.79) | SLC6A2SLC6A4SLC6A3KCNH2CYP2D6 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20120302619-A1 | Novel 1-aryl-3-Azabicyclo[3.1.0]Hexanes: Preparation And Use To Treat Neuropsychiatric Disorders | OTSUKA AMERICA PHARMACEUTICAL, INC. | 2012-11-29 | — | — | US | disclosed |
| US-20090233978-A1 | Novel 1-Aryl-3-Azabicyclo[3.1.0]Hexanes: Preparation And Use To Treat Neuropsychiatric Disorders | OTSUKA AMERICA PHARMACEUTICAL, INC. | 2009-09-17 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120302619-A1 | Novel 1-aryl-3-Azabicyclo[3.1.0]Hexanes: Preparation And Use To Treat Neuropsychiatric Disorders | HTR3C, HTR1B, HTR2C | SLC6A2 276/4885SLC6A4 221/4885SLC6A3 92/4885 |
| US-20090233978-A1 | Novel 1-Aryl-3-Azabicyclo[3.1.0]Hexanes: Preparation And Use To Treat Neuropsychiatric Disorders | HTR3C, HTR1B, HTR2C | SLC6A2 276/4885SLC6A4 221/4885SLC6A3 92/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.